Tissue Transglutaminase-induced Aggregation of Alpha-synuclein: Implications for Lewy Body Formation in Parkinson's Disease and Dementia with Lewy Bodies

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Feb 11

PMID 12576551

Citations 83

Authors

Eunsung Junn

Ruben D Ronchetti

Martha M Quezado

Soo-Youl Kim

M Maral Mouradian

Affiliations

Soon will be listed here.

Abstract

Proteinaceous aggregates containing alpha-synuclein represent a feature of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Despite extensive research, the mechanisms underlying alpha-synuclein aggregation remain elusive. Previously, tissue transglutaminase (tTGase) was found to contribute to the generation of aggregates by cross-linking pathogenic substrate proteins in Huntington's and Alzheimer's diseases. In this article, the role of tTGase in the formation of alpha-synuclein aggregates was investigated. Purified tTGase catalyzed alpha-synuclein cross-linking, leading to the formation of high molecular weight aggregates in vitro, and overexpression of tTGase resulted in the formation of detergent-insoluble alpha-synuclein aggregates in cellular models. Immunocytochemical studies demonstrated the presence of alpha-synuclein-positive cytoplasmic inclusions in 8% of tTGase-expressing cells. The formation of these aggregates was significantly augmented by the calcium ionophore and prevented by the inhibitor cystamine. Immunohistochemical studies on postmortem brain tissue confirmed the presence of transglutaminase-catalyzed epsilon (gamma-glutamyl)lysine cross-links in the halo of Lewy bodies in Parkinson's disease and dementia with Lewy bodies, colocalizing with alpha-synuclein. These findings, taken together, suggest that tTGase activity leads to alpha-synuclein aggregation to form Lewy bodies and perhaps contributes to neurodegeneration.

Citing Articles

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.

A guide to selecting high-performing antibodies for Protein-glutamine gamma-glutamyltransferase 2 (TGM2) for use in western blot, immunoprecipitation and immunofluorescence.

Ayoubi R, Fotouhi M, Alende C, Gonzalez Bolivar S, Southern K, Laflamme C F1000Res. 2024; 13:481.

PMID: 39220380 PMC: 11362715. DOI: 10.12688/f1000research.150684.2.

Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.

Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.

Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.

Liu J, Mouradian M Int J Mol Sci. 2024; 25(4).

PMID: 38397040 PMC: 10888553. DOI: 10.3390/ijms25042364.

References

Lorand L, PARAMESWARAN K, Stenberg P, Tong Y, Velasco P, Jonsson N . Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry. 1979; 18(9):1756-65. DOI: 10.1021/bi00576a019. View

Gomez-Tortosa E, Newell K, Irizarry M, Sanders J, Hyman B . alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 2000; 99(4):352-7. DOI: 10.1007/s004010051135. View

Jensen P, Sorensen E, Petersen T, GLIEMANN J, Rasmussen L . Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J. 1995; 310 ( Pt 1):91-4. PMC: 1135858. DOI: 10.1042/bj3100091. View

Mariani P, Carsughi F, Spinozzi F, Romanzetti S, Meier G, Casadio R . Ligand-induced conformational changes in tissue transglutaminase: Monte Carlo analysis of small-angle scattering data. Biophys J. 2000; 78(6):3240-51. PMC: 1300905. DOI: 10.1016/S0006-3495(00)76860-3. View

Lesort M, Lee M, Tucholski J, Johnson G . Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem. 2002; 278(6):3825-30. DOI: 10.1074/jbc.M205812200. View

Lee S, Kim Y, Junn E, Lee G, Park K, Tanaka M . Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol Aging. 2003; 24(5):687-96. DOI: 10.1016/s0197-4580(02)00196-3. View

Davidson W, Jonas A, Clayton D, George J . Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998; 273(16):9443-9. DOI: 10.1074/jbc.273.16.9443. View

Jenner P, Olanow C . Understanding cell death in Parkinson's disease. Ann Neurol. 1998; 44(3 Suppl 1):S72-84. DOI: 10.1002/ana.410440712. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

10.

Gentile V, Saydak M, Chiocca E, Akande O, Birckbichler P, Lee K . Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem. 1991; 266(1):478-83. View

11.

Lesort M, Tucholski J, Zhang J, JOHNSON G . Impaired mitochondrial function results in increased tissue transglutaminase activity in situ. J Neurochem. 2000; 75(5):1951-61. DOI: 10.1046/j.1471-4159.2000.0751951.x. View

12.

Ho G, Gregory E, Smirnova I, Zoubine M, Festoff B . Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett. 1994; 349(1):151-4. DOI: 10.1016/0014-5793(94)00663-6. View

13.

Karpuj M, Becher M, Steinman L . Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int. 2001; 40(1):31-6. DOI: 10.1016/s0197-0186(01)00060-2. View

14.

Mouradian M . Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology. 2002; 58(2):179-85. DOI: 10.1212/wnl.58.2.179. View

15.

Karpuj M, Becher M, Springer J, Chabas D, Youssef S, Pedotti R . Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002; 8(2):143-9. DOI: 10.1038/nm0202-143. View

16.

Cassarino D, Bennett Jr J . An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev. 1999; 29(1):1-25. DOI: 10.1016/s0165-0173(98)00046-0. View

17.

Engelender S, Kaminsky Z, Guo X, Sharp A, Amaravi R, Kleiderlein J . Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet. 1999; 22(1):110-4. DOI: 10.1038/8820. View

18.

Peterson L, Zettergren J, Wuepper K . Biochemistry of transglutaminases and cross-linking in the skin. J Invest Dermatol. 1983; 81(1 Suppl):95s-100s. DOI: 10.1111/1523-1747.ep12540777. View

19.

Dudek S, JOHNSON G . Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res. 1994; 651(1-2):129-33. DOI: 10.1016/0006-8993(94)90688-2. View

20.

Schapira A . Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal. Mov Disord. 1994; 9(2):125-38. DOI: 10.1002/mds.870090202. View